Department of Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Front Cell Infect Microbiol. 2022 Feb 15;12:834485. doi: 10.3389/fcimb.2022.834485. eCollection 2022.
Type 2 diabetes mellitus (T2DM) is one of the common metabolic diseases in the world. Due to the rise in morbidity and mortality, it has become a global health problem. To date, T2DM still cannot be cured, and its intervention measures mainly focus on glucose control as well as the prevention and treatment of related complications. Interestingly, the gut microbiota plays an important role in the development of metabolic diseases, especially T2DM. In this review, we introduce the characteristics of the gut microbiota in T2DM population, T2DM animal models, and diabetic complications. In addition, we describe the molecular mechanisms linking host and the gut microbiota in T2DM, including the host molecules that induce gut microbiota dysbiosis, immune and inflammatory responses, and gut microbial metabolites involved in pathogenesis. These findings suggest that we can treat T2DM and its complications by remodeling the gut microbiota through interventions such as drugs, probiotics, prebiotics, fecal microbiota transplantation (FMT) and diets.
2 型糖尿病(T2DM)是世界上常见的代谢疾病之一。由于发病率和死亡率的上升,它已成为一个全球性的健康问题。迄今为止,T2DM 仍然无法治愈,其干预措施主要集中在血糖控制以及相关并发症的预防和治疗上。有趣的是,肠道微生物群在代谢性疾病的发展中起着重要作用,特别是在 2 型糖尿病中。在这篇综述中,我们介绍了 T2DM 人群、T2DM 动物模型和糖尿病并发症中肠道微生物群的特征。此外,我们还描述了将宿主与 T2DM 中的肠道微生物群联系起来的分子机制,包括诱导肠道微生物群失调、免疫和炎症反应以及涉及发病机制的肠道微生物代谢物的宿主分子。这些发现表明,我们可以通过药物、益生菌、益生元、粪便微生物移植(FMT)和饮食等干预措施来重塑肠道微生物群,从而治疗 T2DM 及其并发症。